February 19-22, 2023
Seattle, Washington

Conference on Retroviruses and Opportunistic Infections 2023.

Explore more information for Gilead HIV / AIDS therapies
Results (19)

Week 52 subgroup efficacy of lenacapavir in heavily treatment-experienced PWH

Predictors of Hepatitis B treatment response in people with HIV/HBV coinfection

Remdesivir is Associated With Reduced Readmission After COVID-19 Hospitalization

Antiviral activity of lenacapavir against HIV-2 isolates

Lenacapavir with bnabs GS-5423 and GS-2872 dosed every 6 months in people with HIV

Long-acting lenavapavir in a combination regimen for treatment naïve PWH: Week 80

SARS-CoV-2 Replicon System For The Phenotypic Evaluation of NSP Gene Substitutions

Pharmacokinetics Inform Remdesivir Dosing for Patients With Severe Renal Impairment

Remdesivir Retains Potent Activity Against SARS-CoV-2 Omicron Subvariants

Remdesivir Resistance Analyses From The PINETREE Study in Outpatients With COVID-19

8+ years pooled analysis: Adherence and HIV Incidence in 6000 Women on F/TDF for PrEP

Lenacapavir protects against rectal SHIV acquisition in macaque model

Susceptibility screening to bnabs GS-5423 and GS-2872 in art-suppressed patients

Population PK analysis to guide dosing window following lenacapavir SC administration

Six-month outcome of F/TAF cobicistat-boosted darunavir in children 14 to <25kg

Remdesivir Reduces Mortality in Immunocompromised Patients Hospitalized For COVID-19

Remdesivir Reduces Mortality in Hospitalized COVID-19 Patients Across Variant Eras

Heterologous Chad/Samrna SIV vaccine induces robust T cell responses in macaques

Vesatolimod pharmacodynamic response is associated with time to HIV rebound